CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2023 financial results will be released on Tuesday, February 27, 2024 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Visit link:
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00...

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a corporate panel discussion on novel oncology targets at the Cowen 44th Annual Health Care Conference on Tuesday, March 5th, at 9:10 am ET.

Go here to read the rest:
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference

PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market

Follow this link:
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market

Innovations and know-how in exosome production suited for many clinical applications Innovations and know-how in exosome production suited for many clinical applications

Go here to read the rest:
NurExone’s Intellectual Property Portfolio Expands

BRISBANE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on February 16, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).

Read the original post:
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

- Sean Cassidy leaving Arvinas as of February 29, 2024 -

Read more:
Arvinas Announces Chief Financial Officer Transition

REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2023 on Monday, February 26, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress.

Follow this link:
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

Montrouge, France, February 20 2024

Read more:
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

IRVINE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 5 a.m. PT / 8 a.m. ET on Tuesday, February 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.

See the rest here:
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced with sadness that P. Joseph Campisi, Jr., Esq, the Company’s Chief Legal Officer, passed away on February 1, 2024, following a prolonged battle with cancer.

Read the original here:
Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.